Brinzolamide/brimonidine tartrate

PBAC's latest decision on Brinzolamide/brimonidine tartrate: Recommended with restriction (2015). Considered for Treatment of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension whose condition is inadequately controlled with monotherapy.

Eligible population

Adults with open-angle glaucoma or ocular hypertension whose condition is inadequately controlled with monotherapy.

Therapy area

Ophthalmology

Line of therapy

Second-line

Evidence base

RCT

Primary endpoint

IOP

Pivotal trial size

831 patients

Key trials

C-10-041, C-10-040, Kaback 2008

Comparator

brinzolamide 1% and brimonidine tartrate 0.2% administered concomitantly

Economic model

Cost-minimisation

ICER note

Cost-minimisation analysis; no ICER calculated by design.

Similar precedents

• Betaxolol, bimatoprost, bimatoprost + timolol, brimonidine, brimonidine + timolol, brinzolamide, brinzolamide + timolol, dorzolamide, dorzolamide + timolol, latanoprost, latanoprost + timolol, pilocarpine, timolol, travoprost, timolol + travoprost
  similarity 0.82
• Dorzolamide with timolol
  similarity 0.79
• Latanoprost with timolol maleate
  similarity 0.74
• Bimatoprost
  similarity 0.69
• Brolucizumab
  similarity 0.63
• Ranibizumab
  similarity 0.63